Home / Transcripts / Spectral AI, Inc. (MDAI) · May 12, 2026

Spectral AI, Inc. (MDAI) Earnings Call Transcript & Summary

May 12, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 25 min

What were the key takeaways from Spectral AI, Inc.'s May 12, 2026 earnings call?

In Q1 2026, Spectral AI, Inc. reported a decline in R&D revenue to $4 million, down from $6.7 million year-over-year, primarily due to the completion of the Project BioShield contract. The company maintained its revenue guidance for the fiscal year at approximately $18.5 million, which does not include significant contributions from the anticipated commercialization of the DeepView system. Management highlighted progress in FDA discussions and a $31.7 million funding award from BARDA, which is expected to support future growth initiatives.

What topics did Spectral AI, Inc. cover?

What were Spectral AI, Inc.'s May 12, 2026 results?

Spectral AI's Q1 2026 results indicate a cautious but strategic approach as the company prepares for the commercialization of its DeepView system. The secured funding and positive FDA dialogue are significant catalysts, while the ongoing net losses and revenue declines raise concerns. Investors should monitor FDA approval timelines and the execution of the commercialization strategy as key drivers of future performance.

Earnings Call Speaker Segments

Devin Sullivan executive
#1

Thanks, Nick. Hello, everyone, and good afternoon. We appreciate you being on the line for Spectral AI's conference call covering our financial results for the first quarter of 2026. Joining us today are Vincent Capone, who serves as the company's Chief Executive Officer, and David McGuire, our Chief Financial Officer. Before we get started, I want to point out to all of you that some of the remarks on this call constitute forward-looking statements as defined by the safe harbor provisions contained in the United States Private Securities Litigation Reform Act of 1995, and these include statements about the company's strategies, plans, objectives, initiatives, and financial outlook. In this call, terms such as estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future propose, along with variants of those terms or comparable expressions, or their negatives, are meant to signal forward-looking statements. Such forward-looking statements do not represent guarantees of future performance, conditions, or results, and they carry a variety of known and unknown risks, uncertainties, assumptions, and other significant factors, numerous of which lie beyond the company's control, that might lead actual results or outcomes to diverge materially from what is discussed in the forward-looking statements. Because of this, listeners should be warned against placing excessive reliance on any forward-looking statements. Investors ought to thoroughly weigh the factors mentioned above along with additional risks and uncertainties outlined in the Risk Factors section of the company's SEC filings, including the registration statement and other documents the company has filed; those filings point out and cover other material risks and uncertainties that might cause actual events and results to diverge materially from what the forward-looking statements contain. Having said that, I'd like to hand the call over now to Vincent Capone, Chief Executive Officer of Spectral AI. Vince, the floor is yours.

Vincent Capone executive
#2

Thank you, Devin. I'm glad all of you could join us. We published our earnings release this afternoon, and it contains additional details on our operational results. Later tonight, our Form 10-Q will be filed with the SEC. Before we go further, I'd like to introduce David McGuire — this marks his debut earnings call in the role of our new Chief Financial Officer. He joined the company last week and has already been ramping up fast. His background includes more than 20 years at MDAI across a wide range of accounting and finance positions. Naturally, we're thrilled to have him as part of the leadership team. Since we spoke not long ago, I'll keep my remarks fairly brief. As we said before, we filed our De Novo application with the FDA in June of 2025. Since that time, we've responded to further information requests and kept an ongoing dialogue going with the agency. We still expect to hear back from the FDA before the second quarter of this year ends, and after that we're hoping to move fast toward commercializing our DeepView system by the end of 2026. We're carrying out our strategic priorities with a well-capitalized balance sheet, including roughly $11.4 million in cash at quarter's end. Against that backdrop, two words really capture the first quarter: progress and preparation. We've made headway in advancing the DeepView system's development and in keeping up demonstrations of its capabilities for doctors and clinicians around the world. We're getting ready for our primary goal, which is bringing DeepView to market for the burn indication. Progress was evident in March 2026, when we disclosed $31.7 million in advanced funding from BARDA. Under that award, the base phase of our contract received a no-cost extension, and the contract's second phase was accelerated right away, with funding attached to assist and hasten further feature design and components of the DeepView system, as well as to acquire up to 30 devices destined for burn centers, level one trauma centers, and emergency departments. Another sign of preparation was the expansion of our leadership team. As I noted earlier, we now have a new CFO on board. Our hunt for a Chief Commercial Officer has been expanded, and we expect to conclude it before long. Deloitte Consulting remains engaged with us as we finish putting together our commercialization strategy. Last of all, we're wrapping up the protocol for the outcome study. That study is going to focus on what advantages arise when the DeepView system is used throughout clinician workflows and patients' journeys, and we intend for it to cover roughly 240 patients across 12 clinical sites. This outcome study is built to show how the surgical precision comes about when a wound assessment is performed using the DeepView system, and also how speeding up time to treatment decisions by relying on the DeepView system will favorably affect a patient's whole care journey and thus bring down the overall length of stay; in addition, we're working to push forward our international sales strategy. During our March 2025 year-end earnings call, we noted that after we secure FDA clearance, we intend to update the UKCA approval for burn assessment that we received in 2024. That update will bring the approval back in line with the improved algorithm, hardware, and software included in the DeepView system we filed with the FDA. Sales are still projected to begin in late 2026, contingent on the broader UKCA labeling, and those first sales will take place in the U.K., Australia, or the Gulf Cooperation Council nations. I want to spend a moment updating everyone on the handheld unit we're building through our Department of Defense contract, working with the contracting consortium called MTEC. Back in March, during our call about 2025 year-end results, I said we were aiming to hand over a completely working prototype of that device by the time this year's second quarter wrapped up. The good news is that just last week, we got a prototype into MTEC's hands. Later in the year, we're hoping they'll ask us to submit a bid for phase III of the contract, and our plan would be to seek 510(k) clearance for the handheld by relying on our cart-based DeepView system as the predicate. Our presence at the American Burn Association's annual meeting this year was quite strong; that event was held in Orlando during April. More than 2,200 clinicians, researchers, and burn care leaders from across the globe got a good look at the DeepView system, thanks to the platform this conference provided. A number of podium and poster presentations gave the DeepView system a prominent place, and attendees at the ABA Innovation Theater heard Dr. Christopher Lewis give an overview of the technology, covering both his real-world experience and results. Awareness of our DeepView system keeps accelerating because of events such as these. Before we wrap up, I want to mention an honor that came our way quite recently: the Small Business Innovator Award, presented at the first-ever Texas Innovation Conference, which took place on the TCU campus on April 22nd and 23rd. Earning this recognition speaks to how many years we've devoted to rigorous research and to working hand in hand with clinicians, as well as to our dedication to building a technology that addresses a genuine clinical need and can truly make a difference in outcomes for people suffering from burns. Launching the DeepView system commercially isn't where our efforts end. What drives us is bringing this breakthrough to the market in a manner that creates meaningful benefit for patients, for clinicians, for payers, and naturally for our shareholders as well. With that, I'd like to hand the discussion to David, who will walk us through the financial results for our first quarter.

David McGuire executive
#3

Thank you, Vince. It's a thrill to come aboard Spectral AI at such a crucial moment in the company's journey. Throughout my career, I've worked with publicly traded companies to establish finance organizations that can scale, improve capital efficiency, and find funding opportunities. Having gotten to know my new teammates and taken a close look at the DeepView system along with the technology behind it, I'm convinced Spectral AI sits in a strong position to seize a meaningful market opportunity. To repeat Vince's point, I'll be concentrating on making sure the proper financial infrastructure and procedures are in place so we can carry out our strategy. As Vince mentioned, we turned in a strong beginning to the year and stay confident in our capacity to keep up our R&D work and grow into a commercial business. Beginning with the top line, R&D revenue for Q1 of 2026 came in at $4 million, versus $6.7 million. This year-over-year decrease had been expected and was mostly the result of finishing work on the base phase of the company's Project BioShield contract with BARDA; that drop was partly offset by greater activity on other U.S. government contracts, such as the handheld device work Vince brought up earlier. Gross margin for Q1 of 2026 rose by 360 basis points, reaching 50.8%, largely because direct labor made up a bigger share of total revenue. General and administrative expenses dipped modestly to $4.0 million, down from $4.1 million in the same period a year ago, which shows our ongoing cost discipline, partly offset by somewhat higher public company infrastructure costs. Other expense for Q1 2026 totaled $1.5 million, versus other income of $3.9 million in the prior year period. That shift came mainly from non-cash fair value adjustments tied to our warrant liability. Net loss for Q1 2026 was $3.4 million, or $0.11 per diluted share, against net income of $2.9 million, or $0.11 per diluted share. If you set aside the effect of the warrant fair value adjustments in both periods, underlying operating performance was broadly consistent with what we expected. Turning to our financial condition, as of March 31st, 2026, cash stood at $11.7 million, compared with $15.4 million as of December 31st, 2025. Cash use during the quarter mirrored our continued investment in R&D and commercialization initiatives; we stay committed to disciplined capital allocation as we move toward commercialization. As of March 31st, 2026, total debt was $8.5 million, with 31.8 million shares outstanding. All told, we feel we're in a strong position to back the next phase of growth, and I'm eager to connect with many of you over the coming quarters. With that, I'll hand the call over to Vince.

Vincent Capone executive
#4

Appreciate it, David. Ahead of handing things over for Q&A, I'd like to speak to how we see revenue in 2026. As far as this year goes, we're restating our revenue guidance at roughly $18.5 million, and that figure reflects the impact of the accelerated BARDA funding. No meaningful contribution from DeepView system sales is baked into this guidance. With that said, I'll turn it over for any questions.

Ryan Zimmerman analyst
#5

Good afternoon, and thank you for taking our questions, Vince and David. Welcome. Perhaps, to begin, since FDA clearance is potentially so near, Vince, it would be helpful if you could elaborate a bit on the general tone of your discussions, or what you feel at liberty to share, that gives you confidence these timelines will hold for Q2. Then, if you could discuss some of the commercial efforts underway in preparation for DeepView's commercial launch, and I have a follow-up after that.

Vincent Capone executive
#6

Sure, Ryan. A few things, I suppose. We held a number of pre-submission meetings with the FDA before filing our application in June of 2025. Honestly, we had quite a few of those, so our submission felt strong to me; we had a fairly clear sense of what we needed to give the FDA. I believe that since the date we submitted, some of the replies we've received, some of the further information requests, we have kept up, as I mentioned previously, an ongoing dialogue with the FDA. I don't think — I think we're in the best position we can be in, and I think our timeline has stayed solid, with a resolution of our application expected by the close of the second quarter.

Ryan Zimmerman analyst
#7

Okay.

Vincent Capone executive
#8

When it comes to the commercial efforts we've been pursuing as we look to build sales momentum into 2026, the ABA gave us a terrific chance to connect with a number of the people who've been using our device across the U.K. and Australia during roughly the past 12 months. I still believe that securing expanded UKCA labeling, aligned with what we're hoping the FDA will clear, would put us in a solid position to get devices placed in the U.K. Our collaboration with the teams in Australia is ongoing. I'm aware that much of the work being done alongside Dr. Fiona Wood in Perth remains robust. I know they keep using our device. For us, these represent excellent opportunities where we can genuinely create value for, you know, a diverse population of burn patients by demonstrating real benefit in reaching fast treatment decisions for their injuries.

Ryan Zimmerman analyst
#9

Got it. That's a big help. And then, quickly following up on that extra BARDA contract you secured — or rather, that $31.7 million in funding — I realize, Vince, that you aren't going to provide 2027 guidance at this point, but could you offer any big-picture thoughts on the likely rhythm of that contract, or on whether it gets distributed evenly once you start drawing on those funds? Or should we expect peaks and dips, so to speak, in how the development timeline unfolds, as we build out our models?

Vincent Capone executive
#10

Yeah. I think you're raising a solid point regarding that $31.7 million in accelerated funding under phase II; a portion of it will show up during 2026. The sticking point is revenue recognition, which explains why we generally won't record much of it in 2026. A large share ought to be recognized across 2027, particularly as we kick off the economic outcome study; we've put substantial effort into the protocol; that effort will consume part of 2026, yet a big chunk should carry through into 2027. The pattern I'd expect, you know, would be a bit of the $31.7 in 2026, the bulk of it in 2027, and possibly a modest piece left over in 2028.

Ryan Zimmerman analyst
#11

All right, I'll stop with that line of questioning. Thanks for taking the time, and, you know, good work on everything you folks have been accomplishing.

Vincent Capone executive
#12

Appreciate it.

John Vandermosten analyst
#13

Thanks. That's helpful. I want to begin by asking about something; from what I could tell, your team seemed to have a really strong showing at the American Burn Association meeting. What I'd like to know is what sort of things you're picking up from the people involved, such as clinicians and those running hospitals, and so forth. If you've got any informal observations to share regarding the conversations you had or the responses they offered, I'd love to hear them.

Vincent Capone executive
#14

John, it's nice to hear your voice. So, here's the thing — ABA treated us well. It gives us a chance to let folks physically handle the device who might otherwise never have gotten that chance. I felt pretty encouraged by the list of people waiting to potentially get installations that built up while the conference went on. Dr. Christopher Lewis gave a talk in the ABA Innovation Theater that drew a solid crowd, and the findings he shared made a compelling case for what our technology can do when it comes to diagnosing and gauging how severe burn wounds are. From our standpoint, it was a terrific chance. Honestly, we're feeling a fair amount of enthusiasm about getting through Q2, Q3, and Q4 of this year, with the prospect of hopefully reaching commercialization within this year.

John Vandermosten analyst
#15

Understood. Should we prevail in securing that handheld agreement, might there be extra R&D revenue showing up during 2026, or would it instead slip to a later period?

Vincent Capone executive
#16

No, and I appreciate you raising that. That agreement is coming around, and as for finding out if we made the cut to take part in phase III of it, our expectation is that word won't arrive until quite late in 2026. From what I understand, the moment for that decision falls in December of 2026. Nothing from it ought to appear during 2026, and ideally, should we be fortunate enough to be invited into the quote process, a portion of it — in fact the bulk of it — would appear across 2027 and 2028. The effort our team has put into the handheld device makes me genuinely proud. After all, getting a prototype out to MTEC just last week demonstrates how hard our people work to finish things promptly. We're simply going to keep pushing ahead with our objectives and our schedules, aiming to achieve genuine success across 2026 and 2027.

John Vandermosten analyst
#17

Understood. What kind of effort would be required to add the Total Body Surface Area module on top? You previously described that as something like an additional investment your team could put into the product. How challenging would adding it be, given the deployment expected soon? And would regulators create obstacles there, or schedule-related ones, or is it basically a software enhancement you'd be able to deliver?

Vincent Capone executive
#18

A TBSA tool is indeed part of the device we submitted to the FDA, and we're eager to introduce it should the FDA grant approval. Our people have been putting in serious effort on an improvement to it. Internally, we fondly refer to it as TBSA 2, and that software enhancement ought to be ready during 2027. It ought to deliver still more assistance to clinicians and attending physicians so they can give a patient a compelling image plus analysis helping them grasp the proportion of their body that suffered burns, which region will recover, and which region won't. Roughly comparable to giving a patient an X-ray so they can observe the spot where their bone fractured. I'm delighted, you know, that we're able to put a TBSA component into the DeepView system submitted to the FDA, and I'm still more delighted by the effort we're investing in TBSA 2 and eventually perhaps TBSA 3, to genuinely make this capability worthwhile for clinicians.

John Vandermosten analyst
#19

To put TBSA 2 or TBSA 3 on, is there any regulatory process you need to clear?

Vincent Capone executive
#20

As long as the TBSA piece of the DeepView system gets cleared as a De Novo within our De Novo submission, we ought to be fine. What remains could go the 510(k) route — that's really the extent of the complexity. It might not even require a 510(k) at all; that's really the extent of the complexity.

John Vandermosten analyst
#21

All right, understood. Thanks a lot. Appreciate it, Vince.

Vincent Capone executive
#22

You're welcome, John.

Vincent Capone executive
#23

Excellent. I appreciate it. In closing, I'd like once more to express gratitude to those who have invested in us for standing behind this business. I want to restate how thrilled we feel regarding the future in store for this company, for those holding our stock, for the people receiving care, and for the physicians and nurses nationwide and globally. I'd also like to jog your memory about casting your votes on your holdings when our annual meeting takes place soon. Finally, I want to express my thanks to each of you for being here and for the curiosity you've shown in this business, and I wish every one of you a pleasant evening. Thanks so much.

Operator operator
#24

This wraps up our call. We appreciate everyone joining us for today's presentation. You're free to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Spectral AI, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Spectral AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.